RXRX
Recursion Pharmaceuticals, Inc.
October 5, 2026 · intraday
- Rarity
- 1.78
- Peak move
- +19.01%
- Float cap
- $1.9B
Recursion Pharmaceuticals is a clinical-stage TechBio company that uses its Recursion Operating System, an integrated AI-native drug discovery and development platform, to discover and develop differentiated medicines. It advances a pipeline of internal programs and strategic partnerships with biopharmaceutical companies, translating biological insights into therapies for patients. Its platform spans biological data generation, small molecule design, and clinical development.
Where do you see this going?
no votes yetVoting closed at 4:00 PM ET.
What we found
5 events · 0 from SEC or newswire · 0 timed with the moveinstitutional_flowARK Investment Management added Recursion Pharmaceuticals shares, with ARKK raising its holding to 2,669,554 shares (+11.26%) at $4.07 and ARKG adding 152,100 shares, as institutional ownership stood at 76.54%.
insider_saleRecursion Pharmaceuticals director Dean Y. Li acquired 3,378 Class A shares on Oct 1, 2026 under the Outside Director Compensation Policy at $0, bringing his direct holdings to 1,476,707 shares.
borrow_cost_spikeAs October 2026 began, Recursion Pharmaceuticals was among the most heavily shorted mid- to mega-cap US stocks with short interest of 33.4% of shares outstanding, behind Ondas (41.6%) and SoundHound AI (40.1%).
debt_financingRecursion Pharmaceuticals amended its 2023 master data agreement with Tempus AI, extending the term from five to six years, waiving its termination-for-convenience right, and resetting annual license fees to $14M on the third, fourth and fifth anniversaries while reducing the number of de-identified records it can access.
major_contractRecursion Pharmaceuticals entered a two-year, non-exclusive, worldwide RNA Foundation Model License Agreement with Tempus AI for its TxFM RNA sequencing model in oncology, with Tempus paying a $12M non-refundable fee in two $6M installments and supplying de-identified pathology records with linked clinical data.